<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33578">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02060019</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_EXR_101</org_study_id>
    <nct_id>NCT02060019</nct_id>
  </id_info>
  <brief_title>A Phase I Clinical Trial to Investigate the Pharmacokinetic Interactions and Safety Between Exforge Tab. and Crestor Tab. in Healthy Male Subjects</brief_title>
  <official_title>A Phase I Clinical Trial to Investigate the Pharmacokinetic Interactions and Safety Between Exforge Tab. and Crestor Tab. in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CJ HealthCare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CJ HealthCare Corporation</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designated to evaluate the pharmacokinetic interactions of amlodipine
      besylate, valsartan and rosuvastatin in healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2014</start_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Assessment of the drug-drug interactions of amlodipine, valsartan and rosuvastatin: Cmax,ss(Maximum steady-state plasma drug concentration during a dosage interval ), AUCτ(Area Under the Curve)</measure>
    <time_frame>3 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>after steady state (Administration of Investigational Product 7day or 10days)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of the amlodipine, valsartan and rosuvastatin : AUCinf, tmax,ss(Time to reach Cmax,ss), t1/2</measure>
    <time_frame>3 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>steady state (Administration of Investigational Product)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">57</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>exforge 10/160mg(amlodipine 10mg, valsartan160mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 tablet daily for 10days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>crestor 20mg(rosuvastatin 20mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 tablet daily for 7days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>administration of exforge 10/160mg for 3days. Next 7days administration of exforge 10/160mg and crestor 20mg.</intervention_name>
    <arm_group_label>exforge 10/160mg(amlodipine 10mg, valsartan160mg)</arm_group_label>
    <arm_group_label>crestor 20mg(rosuvastatin 20mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male volunteers in the age between 20 and 55 years old

          2. The weight range is not exceed ±20% of ideal weight Ideal weight = [height -100]*0.9

          3. Subjects with no history of any significant chronic disease

          4. Judged to be in good health on the basis of their electrocardiography (ECG) and
             routine laboratory data obtained within 3 weeks prior to study drug administration

          5. Willing to adhere to protocol requirements and sign a informed consent form

        Exclusion Criteria:

          1. History of clinically significant allergies including drug allergies

          2. History of clinically significant hepatic, renal, gastrointestinal, pulmonary,
             ,musculoskeletal, endocrine, psychiatric, hematologic, oncologic, neurologic or
             cardiovascular disease

          3. History of genetic muscluar disease and family history

          4. hyotension (Systolic Blood Pressure(SBP) ≤ 105 or Diastolic Blood Pressure(DBP) ≤ 65)
             or hypertension(SBP ≥ 150 or DBP ≥ 100)

          5. AST(Aspartate Transaminase), ALT(ALanine Transaminase), total bilirubin( &gt; 1.5 times
             to normal range

          6. Creatinine clearance &lt; 80mL/min

          7. Subjects with a history of gastrointestinal diseases which might significantly change
             ADME(Absorption, Distribution, Metabolism and Excretion) of medicines

          8. Serious injury, surjery and acute illness within 4 weeks prior to drug administration

          9. History of alcohol, smoking abuse

               -  alcohol &gt; 21 units/week, 1 unit=10g=12.5mL of pure alcohol

               -  smoking &gt; 10 cigarettes/day

         10. Use of any other medication, including herbal products, within the 2 weeks before
             dosing

         11. Participated in a previous clinical trial within 3 months prior to drug
             administration

         12. Subjects with whole blood donation within 2 months, component blood donation within
             months prior to drug administration

         13. Special diet known to interfere with the absorption, distribution, metabolism or
             excretion of drugs (especially, consumption of grapefruit juice) within 7 days prior
             to drug administration

         14. Clinical laboratory test values are positive (HBsAg, HCV Ab, HIV Ag/Ab, VDRL)

         15. Subjects considered as unsuitable based on medical judgement by investigators
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young Ran Yoon PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyungpook university hostipal</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Geun-Seog Song, PhD</last_name>
    <phone>82-2-6740-2440</phone>
    <email>kssong1212@cj.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eun-Ji Kim</last_name>
    <phone>82-2-6740-2443</phone>
    <email>keunji@cj.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kyungpook university hospital</name>
      <address>
        <city>Deagu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 9, 2014</lastchanged_date>
  <firstreceived_date>February 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rosuvastatin</mesh_term>
    <mesh_term>Amlodipine, valsartan drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
